Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia

Xia Li; Xiufeng Yin; Huafeng Wang; Jiansong Huang; Mengxia Yu; Zhixin Ma; Chenying Li; Yile Zhou; Xiao Yan; ShuJuan Huang; Jie Jin

doi:10.18632/oncotarget.27310

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia

Oncotarget. 2019 Nov 12;10(61):6641-6642. doi: 10.18632/oncotarget.27310.

Authors

Xia Li^#^{1

2}, Xiufeng Yin^#^{1

2}, Huafeng Wang^{1

2}, Jiansong Huang^{1

2}, Mengxia Yu^{1

2}, Zhixin Ma^{1

2}, Chenying Li^{1

2}, Yile Zhou^{1

2}, Xiao Yan^{1

2}, ShuJuan Huang^{1

2}, Jie Jin^{1

2

3}

Affiliations

¹ Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, People's Republic of China.
² Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
³ Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.14463.].

Publication types

Published Erratum